Is buspirone safe to use during pregnancy, and what are the recommendations regarding dosage and breastfeeding?

Buspirone Use During Pregnancy and Breastfeeding

Buspirone can be used during pregnancy when clinically necessary, as animal studies show no fetal harm at 30 times the human dose and preliminary human data from 68 pregnancies revealed no major malformations, though it should only be prescribed when the benefit clearly justifies any potential risk. 1, 2

Pregnancy Safety Profile

FDA Classification and Animal Data

Buspirone is FDA Pregnancy Category B, meaning animal reproduction studies at approximately 30 times the maximum recommended human dose showed no fertility impairment or fetal damage in rats and rabbits 1. However, adequate and well-controlled studies in pregnant women have not been performed, which is the critical limitation.

Human Pregnancy Data

The most relevant evidence comes from the Massachusetts General Hospital National Pregnancy Registry (2022), which prospectively followed 68 evaluable women who took buspirone during their first trimester, resulting in 72 infants (including 4 sets of twins). Importantly, zero major malformations were observed in this rigorously ascertained cohort 2. While this sample size is modest, the prospective methodology and complete absence of malformations is reassuring.

Clinical Decision Framework

Use buspirone during pregnancy when:

• The maternal anxiety disorder poses significant risk to maternal or fetal health if untreated
• Alternative treatments with more extensive pregnancy data (such as SSRIs) are ineffective, contraindicated, or poorly tolerated
• The patient has been stable on buspirone pre-pregnancy and switching medications poses greater risk

Key principle: The FDA label explicitly states the drug "should be used during pregnancy only if clearly needed" 1. This aligns with the general pregnancy medication framework that maternal benefit must justify potential fetal risk 3.

Dosing During Pregnancy

Standard adult dosing applies (typically 15-30 mg/day divided into 2-3 doses, maximum 60 mg/day). No specific dose adjustments are recommended for pregnancy in the FDA labeling 1. The registry data included women taking 7.5-30 mg twice daily without observed malformations 2.

Breastfeeding Recommendations

Buspirone should be avoided during breastfeeding if clinically possible, but when necessary, the infant exposure appears minimal and likely safe based on recent pharmacokinetic data. 1, 4

Transfer into Breast Milk

A 2024 study of 9 lactating mothers taking buspirone 7.5-30 mg twice daily found:

• Buspirone itself was undetectable (below 1.5 ng/mL) in all milk samples
• The active metabolite 1-pyrimidinylpiperazine (1-PP) was present at low levels
• Relative Infant Dose (RID) ranged from 0.21% to 2.17%, well below the 10% safety threshold 4
• No adverse effects were reported in any exposed infants 4

Practical Breastfeeding Guidance

The FDA label states that buspirone and metabolites are excreted in rat milk, and "administration to nursing women should be avoided if clinically possible" 1. However, the 2024 human data suggests actual infant exposure is clinically insignificant 4.

When buspirone is necessary during breastfeeding:

• Inform mothers that infant drug exposure is minimal (RID <2.2%)
• Monitor infants for sedation, poor feeding, or developmental concerns
• Consider timing doses after breastfeeding to minimize infant exposure, though given the low RID this may not be necessary
• Document that alternative anxiolytics (benzodiazepines) carry their own breastfeeding concerns

Important Caveats and Monitoring

Drug Interactions During Pregnancy/Lactation

• Avoid MAO inhibitors (contraindicated; must discontinue 14 days before buspirone) 1
• CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, ketoconazole) significantly increase buspirone levels—use lowest effective dose if combination necessary 1
• Grapefruit juice should be avoided as it inhibits CYP3A4 1

Hepatic/Renal Impairment

Buspirone is metabolized by the liver and excreted by the kidneys. Severe hepatic or renal impairment is a relative contraindication due to increased plasma levels and prolonged half-life 1. This is particularly relevant as pregnancy can affect hepatic and renal function.

Laboratory Interference

Discontinue buspirone 48 hours before urine catecholamine testing for pheochromocytoma, as it causes false-positive metanephrine results 1.

Comparison to Alternative Anxiolytics

While not directly addressed in the provided evidence for buspirone, the general pregnancy medication framework 3 emphasizes weighing risks of untreated maternal disease against medication risks. For anxiety disorders:

• SSRIs have more extensive pregnancy safety data but carry their own risks
• Benzodiazepines have concerns for neonatal withdrawal and sedation
• Untreated anxiety can lead to poor prenatal care, substance use, and adverse pregnancy outcomes

The decision to use buspirone should balance its limited but reassuring human pregnancy data against the specific clinical context and available alternatives.